Ted Myles

Ted is a CEO-Partner at Flagship Pioneering and Chief Executive Officer of Cellarity. He is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. 

Ted was most recently at Scholar Rock, where he served as Chief Financial Officer (CFO) and Chief Operating Officer (COO). During his tenure, Myles led the company through its evolution from early development-stage through a successful Phase 3 registrational study and raised more than $1 billion in capital to advance the company’s product and pipeline strategy. Previously, he served as CFO and COO of AMAG Pharmaceuticals, Inc. (acquired by Covis Pharmaceuticals), CFO and COO of Ocata Therapeutics, Inc. (acquired by Astellas), and CFO and Vice President of Operations at PrimeraDx, Inc. (acquired by Qiagen). Earlier in his career, Myles worked at EMD Pharmaceuticals (now EMD Serono, a part of Merck KGaA), SG Cowen Securities Corporation in the healthcare investment banking group and Coopers & Lybrand LLP.

He holds an MBA from John M. Olin School of Business at Washington University in St. Louis and a B.S. in Business Administration from the University of Hartford.